Synthetic peptide of tumor associated antigen L6-based cancer immunotherapy
腫瘤相關抗原合成肽 基於L6的癌症免疫療法
Synthetic peptide of tumor associated antigen L6-based cancer immunotherapy
腫瘤相關抗原合成肽 基於L6的癌症免疫療法
Targeted indication
Lung, breast and colorectal cancer
Status
Preclinical study
Key features
- High safety profile
- Easy to manufacture
- Less barrier to enter clinical trials
Market
Synthetic peptide is an attractive approach for cancer immunotherapy because of its safety and flexibility. Although there are many peptide-based cancer immunotherapy have been performed in clinical trials, synthetic peptide contains both B and T cell epitopes is very few. There are no synthetic peptide products have been used to target TAL6-associated cancers (lung cancer, Breast cancer, Colorectal cancer...etc). Our invention could be an innovative approach to treat cancers.
MODE OF ACTION
EXPERIMENTAL RESULTS
Synthetic peptide immunization induced strong ADCC and CTL responses
Peptide immunization can inhibit tumor growth and cancer cell migration
Non-toxic in Single Dose Acute Toxicity Testing (At doses up to 10 times of the effective dose in animal).
N/A
INTELLECTUAL PROPERTY
SELECTED PUBLICATIONS
1. Lin et al. Cancer Letters.377(2):126-33.2016
2. Sher et al. Oncotarget, 2016 7(1):671-683
3. Tu et al. J. Immunotherapy. 35:235-244, 2012
BUSINESS OPPORTUNITY
License and/or Collaboration and Sponsored Research
CONTACT
service@biip-dcc.org